BioWorld

April 28, 2008

Astellas, CoMentis in $760M Deal for Alzheimer's Treatment

Japanese drugmaker Astellas Pharma Inc. is partnering with CoMentis Inc. to develop a compound for Alzheimer's disease under a deal potentially worth $760 million for the latter. (BioWorld Today) Read More

FDA OKs Progenics Drug; EMA also Gives It a Nod

Japan Pharmas' Love for U.S. Biotechs Just Heating Up

Observational Trials Have Merits, but Stark Limits also Apparent

Amgen Posts Flat 1st Quarter, as Future Hinges on Denosumab

Isis Shares Slip on Need for Mipomersen Data

House Measure Reauthorizes BIO-Backed SBIR Grants

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...